Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
Wagemann O, Liu H, Wang G, Shi X, Bittner T, Scelsi MA, Farlow MR, Clifford DB, Supnet-Bell C, Santacruz AM, Aschenbrenner AJ, Hassenstab JJ, Benzinger TLS, Gordon BA, Coalier KA, Cruchaga C, Ibanez L, Perrin RJ, Xiong C, Li Y, Morris JC, Lah JJ, Berman SB, Roberson ED, van Dyck CH, Galasko D, Gauthier S, Hsiung GR, Brooks WS, Pariente J, Mummery CJ, Day GS, Ringman JM, Mendez PC, St George-Hyslop P, Fox NC, Suzuki K, Okhravi HR, Chhatwal J, Levin J, Jucker M, Sims JR, Holdridge KC, Proctor NK, Yaari R, Andersen SW, Mancini M, Llibre-Guerra J, Bateman RJ, McDade E; Dominantly Inherited Alzheimer Network–Trials Unit. Wagemann O, et al. Among authors: aschenbrenner aj. JAMA Neurol. 2024 Apr 29:e240991. doi: 10.1001/jamaneurol.2024.0991. Online ahead of print. JAMA Neurol. 2024. PMID: 38683602 Free PMC article.
Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN).
Aschenbrenner AJ, James BD, McDade E, Wang G, Lim YY, Benzinger TLS, Cruchaga C, Goate A, Xiong C, Perrin R, Buckles V, Allegri R, Berman SB, Chhatwal JP, Fagan A, Farlow M, O'Connor A, Ghetti B, Graff-Radford N, Goldman J, Gräber S, Karch CM, Lee JH, Levin J, Martins RN, Masters C, Mori H, Noble J, Salloway S, Schofield P, Morris JC, Bateman RJ, Hassenstab J; Dominantly Inherited Alzheimer Network. Aschenbrenner AJ, et al. Alzheimers Dement. 2020 Jan;16(1):219-228. doi: 10.1002/alz.12010. Alzheimers Dement. 2020. PMID: 31914221 Free PMC article.
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
Salloway S, Farlow M, McDade E, Clifford DB, Wang G, Llibre-Guerra JJ, Hitchcock JM, Mills SL, Santacruz AM, Aschenbrenner AJ, Hassenstab J, Benzinger TLS, Gordon BA, Fagan AM, Coalier KA, Cruchaga C, Goate AA, Perrin RJ, Xiong C, Li Y, Morris JC, Snider BJ, Mummery C, Surti GM, Hannequin D, Wallon D, Berman SB, Lah JJ, Jimenez-Velazquez IZ, Roberson ED, van Dyck CH, Honig LS, Sánchez-Valle R, Brooks WS, Gauthier S, Galasko DR, Masters CL, Brosch JR, Hsiung GR, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Jack CR Jr, Koeppe R, Snyder PJ, Aisen PS, Thomas RG, Berry SM, Wendelberger BA, Andersen SW, Holdridge KC, Mintun MA, Yaari R, Sims JR, Baudler M, Delmar P, Doody RS, Fontoura P, Giacobino C, Kerchner GA, Bateman RJ; Dominantly Inherited Alzheimer Network–Trials Unit. Salloway S, et al. Among authors: aschenbrenner aj. Nat Med. 2021 Jul;27(7):1187-1196. doi: 10.1038/s41591-021-01369-8. Epub 2021 Jun 21. Nat Med. 2021. PMID: 34155411 Free PMC article. Clinical Trial.
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
Wang G, Li Y, Xiong C, McDade E, Clifford DB, Mills SL, Santacruz AM, Aschenbrenner AJ, Hassenstab J, Benzinger TLS, Gordon BA, Fagan AM, Coalier KA, Libre-Guerra JJ, McCullough A, Joseph-Mathurin N, Chen CD, Mummery C, Wendelberger BA, Gauthier S, Masellis M, Holdridge KC, Yaari R, Chatterjee S, Sims J, Delmar P, Kerchner GA, Bittner T, Hofmann C, Bateman RJ; DIAN‐TU Study Team. Wang G, et al. Among authors: aschenbrenner aj. Alzheimers Dement (Amst). 2022 Nov 3;14(1):e12367. doi: 10.1002/dad2.12367. eCollection 2022. Alzheimers Dement (Amst). 2022. PMID: 36348972 Free PMC article.
Investigation of sex differences in mutation carriers of the Dominantly Inherited Alzheimer Network.
Wagemann O, Li Y, Hassenstab J, Aschenbrenner AJ, McKay NS, Gordon BA, Benzinger TLS, Xiong C, Cruchaga C, Renton AE, Perrin RJ, Berman SB, Chhatwal JP, Farlow MR, Day GS, Ikeuchi T, Jucker M, Lopera F, Mori H, Noble JM, Sánchez-Valle R, Schofield PR, Morris JC, Daniels A, Levin J, Bateman RJ, McDade E, Llibre-Guerra JJ; Dominantly Inherited Alzheimer Network. Wagemann O, et al. Among authors: aschenbrenner aj. Alzheimers Dement. 2024 Jan;20(1):47-62. doi: 10.1002/alz.13460. Epub 2023 Sep 23. Alzheimers Dement. 2024. PMID: 37740921 Free PMC article.
Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease.
Wang G, Li Y, Xiong C, Benzinger TLS, Gordon BA, Hassenstab J, Aschenbrenner AJ, McDade E, Clifford DB, Libre-Guerra JJ, Shi X, Mummery CJ, van Dyck CH, Lah JJ, Honig LS, Day G, Ringman JM, Brooks WS, Fox NC, Suzuki K, Levin J, Jucker M, Delmar P, Bittner T, Bateman RJ; DIAN‐TU Study Team. Wang G, et al. Among authors: aschenbrenner aj. Alzheimers Dement. 2024 Apr;20(4):2698-2706. doi: 10.1002/alz.13735. Epub 2024 Feb 23. Alzheimers Dement. 2024. PMID: 38400532 Free PMC article.
Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease.
Wang G, Xiong C, McDade EM, Hassenstab J, Aschenbrenner AJ, Fagan AM, Benzinger TLS, Gordon BA, Morris JC, Li Y, Bateman RJ; Dominantly Inherited Alzheimer Network (DIAN). Wang G, et al. Among authors: aschenbrenner aj. Alzheimers Dement (N Y). 2018 Dec 7;4:669-676. doi: 10.1016/j.trci.2018.10.009. eCollection 2018. Alzheimers Dement (N Y). 2018. PMID: 30569014 Free PMC article.
Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.
Gordon BA, Blazey TM, Christensen J, Dincer A, Flores S, Keefe S, Chen C, Su Y, McDade EM, Wang G, Li Y, Hassenstab J, Aschenbrenner A, Hornbeck R, Jack CR, Ances BM, Berman SB, Brosch JR, Galasko D, Gauthier S, Lah JJ, Masellis M, van Dyck CH, Mintun MA, Klein G, Ristic S, Cairns NJ, Marcus DS, Xiong C, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS. Gordon BA, et al. Brain. 2019 Apr 1;142(4):1063-1076. doi: 10.1093/brain/awz019. Brain. 2019. PMID: 30753379 Free PMC article.
61 results